President Trump’s proposed 10% import tariffs could disrupt U.S. MedTech supply chains, triggering delays, higher production costs, and complex FDA compliance risks. With nearly 40% of devices relying on imports, companies face tough decisions around sourcing, manufacturing, and long-term resilience. Marcel Botha, CEO of 10XBeta, shares strategies for navigating this volatile landscape and building stronger, smarter supply chains.
Read the Full Article.
About
TechTarget
Informa TechTarget is a trusted global partner of leading B2B brands and dynamic start-ups alike. Committed to accelerating growth for businesses everywhere, we harness the insights of over 750 experts across a network of more than 220 digital properties to guide and shape the critical decisions of our industry. As a key information resource within the tech, we understand what’s happening in critical markets to support tech buyers’ solution-oriented decision-making every second of every day.
ABOUT THE Author
Alivia Kaylor, MSc
Senior Editor, Xtelligent/TechTarge
Alivia is a senior editor for Pharma Life Sciences, which provides essential news in the pharmaceutical and life sciences industries. Previously, she was an assistant editor at the American Chemical Society, a leading nonprofit in peer-reviewed scientific research publishing. She has also worked as an environmental monitoring technician and quality control microbiologist at American Regent, a Daiichi Sankyo company specializing in sterile injectable drugs.
Alivia holds a bachelor's degree in microbiology from Ohio State University. In 2023, Alivia earned a master's degree in Sustainability, Security, and Resilience from Ohio University's Voinovich School of Leadership and Public Service.
